The MarketWatch News Department was not involved in the creation of this content. BEDFORD, Mass., July 29, 2025 /PRNewswire/ -- Werfen today announced the expansion of commercialization for the GEM ...

BEDFORD, Mass., July 29, 2025 /PRNewswire/ -- Werfen today announced the expansion of commercialization for the GEM Premier 7000 with iQM3 blood gas testing system, following its success in North ...

— Underlines Werfen's Leadership in Innovation with the Introduction of Hemolysis Detection at the Point of Care— BEDFORD, Mass., May 1, 2025 /PRNewswire/ -- Werfen today announced they have been ...

—Delivering Optimized Workflow Across the Hemostasis Laboratory Network with a Powerful Combination of Quality and Efficiency— To streamline and optimize workflow, ACL TOP Family 70 Series systems ...

Hepzato Kit, FDA-approved for metastatic uveal melanoma liver treatment, shows strong early revenue ($10M in Q3, $13.7M expected in Q4) with surprising profitability. The disease affects ~1,700 ...

BEDFORD, Mass., Dec. 3, 2024 /PRNewswire/ -- Werfen today announced the opening of a new building, expanding its capabilities for innovation in Specialized Diagnostics, at its Hemostasis and Acute ...

3/4 Introducing Hemolysis Detection in Point-of-Care Blood Gas Testing for the First Time Ever 3/4 BEDFORD, Mass., July 30, 2024 /PRNewswire/ -- Werfen today announced the introduction of the GEM ...

Investors with any experience in the world of penny stocks know that risk is real. That risk is higher as the price of shares goes lower. Thus, stocks trading between $5 and $10 are somewhat more ...

The Aptiva APS IgG and APS IgM reagents are immunoassays that utilize Aptiva particle-based multi-analyte technology (PMAT) for the semi-quantitative determination of anti-cardiolipin (aCL) and ...